Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

OPKO Health Inc OPK

Healthcare
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.


NDAQ:OPK - Post by User

OPKO Health Inc
<< Previous
 Bullboard Posts
User Avatar Image
(229)
•••
Post by whytestockson Sep 17, 2024 6:02pm
55 Views
Post# 36228020

Overweight Recommendation Issued On OPK By Piper Sandler

Overweight Recommendation Issued On OPK By Piper Sandler
Breaking News: $OPK Overweight Recommendation Issued On OPK By Piper Sandler2024-09-17 12:15:08 ET Piper Sandler analyst issues OVERWEIGHT recommendation for OPK on September 17, 2024 07:15AM ET. The previous analyst recommendation was Overweight. OPK was trading at $1.73 at issue of the analyst recommendation. The overall analyst consensus : HO...OPK - Overweight Recommendation Issued On OPK By Piper Sandler

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities